文献速递肾癌与肾肿瘤

机器人辅助对比传统开放肾部分切除术的随机对照可行性试验:ROBOCOP II研究

Randomized Controlled Feasibility Trial of Robot-assisted Versus Conventional Open Partial Nephrectomy: The ROBOCOP II Study.
PubMed 文献 · Eur Urol Oncol · 2023-06-12

ROBOCOP II为单中心、开放标签、可行性随机对照试验,将疑似局限性肾细胞癌拟行肾部分切除术患者按1:1随机分配至机器人辅助肾部分切除术(RAPN)或开放肾部分切除术(OPN)。共50例患者接受手术,入组率65%。RAPN较OPN出血量更少、阿片类药物需求更低、并发症更少,但OPN手术时间和热缺血时间更短;两种术式术后肾功能无差异。

要点

  • RAPN较OPN出血量减少212 ml(95%CI 105-320,p<0.001),阿片类药物需求降低30%(95%CI 5-54,p=0.024)。
  • RAPN较OPN平均综合并发症指数降低9(95%CI 0-18,p=0.008)。
  • OPN较RAPN手术时间缩短18 min(95%CI -35至-1,p=0.046),热缺血时间缩短6.7 min(95%CI -10.7至-2.7,p=0.001)。

核心结论

  • 本首个比较OPN与RAPN的随机对照试验达到了招募可行性主要结局,但未来随机对照试验的窗口正在关闭。
  • 每种术式各有优势,两者均为安全有效的选择。

研究设计与样本

  • ROBOCOP II为单中心、开放标签、可行性随机对照试验。
  • 疑似局限性肾细胞癌拟行肾部分切除术患者按1:1随机分配至RAPN或OPN。
  • 共50例患者接受RAPN或OPN,入组率65%。
  • 数据在改良意向治疗人群中描述性分析,该人群由随机分组后接受手术的患者组成。

主要发现

  • RAPN较OPN出血量更低(OPN 361 ml,SD 238;RAPN 149 ml,SD 122;差值212 ml,95%CI 105-320;p<0.001)。
  • RAPN较OPN阿片类药物需求更少(OPN 46%;RAPN 16%;差值30%,95%CI 5-54;p=0.024)。
  • RAPN较OPN平均综合并发症指数更低(OPN 14,SD 16;RAPN 5,SD 15;差值9,95%CI 0-18;p=0.008)。
  • OPN较RAPN手术时间更短(OPN 112 min,SD 29;RAPN 130 min,SD 32;差值-18 min,95%CI -35至-1;p=0.046)。
  • OPN较RAPN热缺血时间更短(OPN 8.7 min,SD 7.1;RAPN 15.4 min,SD 7.0;差值6.7 min,95%CI -10.7至-2.7;p=0.001)。

关键数值与推荐

  • RAPN与OPN术后肾功能无差异。
  • RAPN较OPN出血量差值212 ml(95%CI 105-320;p<0.001)。
  • RAPN较OPN阿片类药物需求差值30%(95%CI 5-54;p=0.024)。
  • RAPN较OPN平均综合并发症指数差值9(95%CI 0-18;p=0.008)。
  • OPN较RAPN手术时间差值-18 min(95%CI -35至-1;p=0.046),热缺血时间差值6.7 min(95%CI -10.7至-2.7;p=0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is no evidence from randomized controlled trials (RCTs) comparing robot-assisted partial nephrectomy (RAPN) and open partial nephrectomy (OPN). OBJECTIVE: To assess the feasibility of trial recruitment and to compare surgical outcomes between RAPN and OPN. DESIGN, SETTING, AND PARTICIPANTS: ROBOCOP II was designed as single-center, open-label, feasibility RCT. Patients with suspected localized renal cell carcinoma referred for PN were randomized at a 1:1 ratio to either RAPN or OPN. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was the feasibility of recruitment, assessed as the accrual rate. Secondary outcomes included perioperative and postoperative data. Data were analyzed descriptively in a modified intention-to-treat population consisting of randomized patients who underwent surgery. RESULTS AND LIMITATIONS: A total of 50 patients underwent RAPN or OPN (accrual rate 65%). In comparison to OPN, RAPN had lower blood loss (OPN 361 ml, standard deviation [SD] 238; RAPN 149 ml, SD 122; difference 212 ml, 95% confidence interval [CI] 105-320; p < 0.001), less need for opioids (OPN 46%; RAPN 16%; difference 30%, 95% CI 5-54; p = 0.024), and fewer complications according to the mean Comprehensive Complication Index (OPN 14, SD 16; RAPN 5, SD 15; difference 9, 95% CI 0-18; p = 0.008). OPN has a shorter operative time (OPN 112 min, SD 29; RAPN 130 min, SD 32; difference -18 min, 95% CI -35 to -1; p = 0.046) and warm ischemia time (OPN 8.7 min, SD 7.1; RAPN 15.4 min, SD 7.0; difference 6.7 min, 95% CI -10.7 to -2.7; p = 0.001). There were no differences between RAPN and OPN regarding postoperative kidney function. CONCLUSIONS: This first RCT comparing OPN and RAPN met the primary outcome of the feasibility of recruitment; however, the window for future RCTs is closing. Each approach has advantages over the other, and both remain safe and effective options. PATIENT SUMMARY: For patients with a kidney tumor, open surgery and robot-assisted keyhole surgery are both feasible and safe approaches for partial removal of the affected kidney. Each approach has known advantages. Long-term follow-up will explore differences in quality of life and cancer control outcomes.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Kowalewski KF, Neuberger M, Sidoti Abate MA, et al. Randomized Controlled Feasibility Trial of Robot-assisted Versus Conventional Open Partial Nephrectomy: The ROBOCOP II Study. Eur Urol Oncol. 2023. PMID: 37316398. doi:10.1016/j.euo.2023.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。